Betatrophin is downregulated in pregnant women with a history of RYGB operation and a high risk of postprandial hypoglycaemia.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 08 2020
04 08 2020
Historique:
received:
28
02
2020
accepted:
22
06
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Betatrophin is a liver and adipose tissue-derived protein which has recently been linked to glucose metabolism. So far, no data exist about the role of betatrophin in pregnant women with a history of Roux-En-Y gastric bypass (RYGB) operation with a high risk of postprandial hypoglycaemia. In this prospective clinical study, an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performed between the 24th and 28th week of pregnancy and 3-6 months post-partum in a cohort of obese and normal-weight pregnant women, as well as in women with a history of RYGB operation. In the cohort of pregnant women with RYGB and exaggerated risk of postprandial hypoglycaemic events, basal and dynamic betatrophin levels during the OGTT were lower than in the obese or normal-weight pregnant women (basal levels: 13.66 ± 5.88 vs. 19.03 ± 4.15 vs. 15.68 ± 6.48, p = 0.016; OGTT 60': 13.33 ± 5.40 vs. 17.37 ± 3.16 vs. 15.84 ± 4.99, p = 0.030). During the OGTT, basal and dynamic betatrophin levels at 60' were positively associated with glucose levels at 60 min (r = 0.55, p = 0.01 and r = 0.45, p = 0.039). This positive association was followed by significant hypoglycaemic events in the RYGB group. It was only in the RYGB group that betatrophin was negatively related to the disposition index (rho = -0.53, p = 0.014). After pregnancy there was a decrease in basal and stimulated betatrophin levels during the OGTT in all three patient groups. In comparison to normal-weight and obese pregnant women, women with a history of RYGB operation and a high risk of postprandial hypoglycaemic events have lower levels of betatrophin. This indicate a mechanistic role in order to decrease the risk of postprandial hypoglycaemia in this specific cohort.
Identifiants
pubmed: 32753693
doi: 10.1038/s41598-020-70075-1
pii: 10.1038/s41598-020-70075-1
pmc: PMC7403341
doi:
Substances chimiques
ANGPTL8 protein, human
0
Angiopoietin-Like Protein 8
0
Angiopoietin-like Proteins
0
Peptide Hormones
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13152Références
Ren, G., Kim, J. Y. & Smas, C. M. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 303(3), E334–E351 (2012).
doi: 10.1152/ajpendo.00084.2012
Chi, X. et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol. Metab. 6(10), 1137–1149 (2017).
doi: 10.1016/j.molmet.2017.06.014
Fu, Z. et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci. Rep. 4, 5013 (2014).
doi: 10.1038/srep05013
Fenzl, A. et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 57(6), 1204–1208 (2014).
doi: 10.1007/s00125-014-3208-x
Gao, T. et al. Circulating betatrophin correlates with triglycerides and postprandial glucose among different glucose tolerance statuses: A case-control study. PLoS ONE 10(8), e0133640 (2015).
doi: 10.1371/journal.pone.0133640
Chen, X. et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J. Clin. Endocrinol. Metab. 100(1), E96-100 (2015).
doi: 10.1210/jc.2014-2300
Espes, D., Martinell, M. & Carlsson, P. O. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int. J. Endocrinol. 2014, 323407 (2014).
doi: 10.1155/2014/323407
Yue, S., Wu, J., Zhang, J., Liu, L. & Chen, L. The relationship between betatrophin levels in blood and T2DM: A systematic review and meta-analysis. Dis. Markers. 2016, 9391837 (2016).
doi: 10.1155/2016/9391837
Hu, H. et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care 37(10), 2718–2722 (2014).
doi: 10.2337/dc14-0602
Ebert, T. et al. Betatrophin levels are increased in women with gestational diabetes mellitus compared to healthy pregnant controls. Eur. J. Endocrinol. 173(1), 1–7 (2015).
doi: 10.1530/EJE-14-0815
Trebotic, L. K. et al. Circulating betatrophin is strongly increased in pregnancy and gestational diabetes mellitus. PLoS ONE 10(9), e0136701 (2015).
doi: 10.1371/journal.pone.0136701
Shankar, S. S. et al. Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes. BMC Obes. 4, 10 (2017).
doi: 10.1186/s40608-017-0149-1
Schauer, P. R. et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann. Surg. 238(4), 467–484 (2003) (discussion 84–85).
pubmed: 14530719
pmcid: 1360104
Leutner, M. et al. Glucagon-like peptide 1 (GLP-1) drives postprandial hyperinsulinemic hypoglycemia in pregnant women with a history of Roux-en-Y gastric bypass operation. Metabolism. 91, 10–17 (2019).
doi: 10.1016/j.metabol.2018.10.006
Salehi, M., Vella, A., McLaughlin, T. & Patti, M. E. Hypoglycemia after gastric bypass surgery: Current concepts and controversies. J. Clin. Endocrinol. Metab. 103(8), 2815–2826 (2018).
doi: 10.1210/jc.2018-00528
Schauer, P. R., Ikramuddin, S., Gourash, W., Ramanathan, R. & Luketich, J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann. Surg. 232(4), 515–529 (2000).
doi: 10.1097/00000658-200010000-00007
Adams, T. D. et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377(12), 1143–1155 (2017).
doi: 10.1056/NEJMoa1700459
Göbl, C. S. et al. Assessment of glucose regulation in pregnancy after gastric bypass surgery. Diabetologia 60(12), 2504–2513 (2017).
doi: 10.1007/s00125-017-4437-6
Bozkurt, L., Göbl, C. S., Leutner, M., Eppel, W. & Kautzky-Willer, A. Bariatric surgery impacts levels of serum lipids during pregnancy. Obes Facts. 13(1), 58–65 (2020).
Zhang, R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem. Biophys. Res. Commun. 424(4), 786–792 (2012).
doi: 10.1016/j.bbrc.2012.07.038
Espes, D., Lau, J. & Carlsson, P. O. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 57(1), 50–53 (2014).
doi: 10.1007/s00125-013-3071-1
Liu, D. et al. Relationship between serum betatrophin levels and the first-phase of glucose-stimulated insulin secretion. Obes. Res. Clin. Pract. 12(Suppl 2), 9–15 (2018).
doi: 10.1016/j.orcp.2016.08.004
Liu, D. et al. Increased circulating full-length betatrophin levels in drug-naive metabolic syndrome. Oncotarget. 8(11), 17510–17517 (2017).
doi: 10.18632/oncotarget.15102
Wang, H. et al. Circulating betatrophin is associated with insulin resistance in humans: Cross-sectional and interventional studies in vivo and in vitro. Oncotarget. 8(57), 96604–96614 (2017).
doi: 10.18632/oncotarget.21852
Abu-Farha, M. et al. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovasc. Diabetol. 15, 25 (2016).
doi: 10.1186/s12933-016-0346-0
Rong Guo, X. et al. ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3beta or Akt-FoxO1 pathway in HepG2 cells. Exp. Cell Res. 345(2), 158–167 (2016).
doi: 10.1016/j.yexcr.2015.09.012
Buchanan, T. A. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9), 2796–2803 (2002).
doi: 10.2337/diabetes.51.9.2796
Utzschneider, K. M. et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32(2), 335–341 (2009).
doi: 10.2337/dc08-1478
Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444(7121), 840–846 (2006).
doi: 10.1038/nature05482
Lain, K. Y. & Catalano, P. M. Metabolic changes in pregnancy. Clin. Obstet. Gynecol. 50(4), 938–948 (2007).
doi: 10.1097/GRF.0b013e31815a5494
Barbour, L. A. et al. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 30(Suppl 2), S112–S119 (2007).
doi: 10.2337/dc07-s202
Siddiqa, A. et al. Biological pathways leading from ANGPTL8 to diabetes mellitus-A co-expression network based analysis. Front. Physiol. 9, 1841 (2018).
doi: 10.3389/fphys.2018.01841
Lu, P. et al. Insulin upregulates betatrophin expression via PI3K/Akt pathway. Sci. Rep. 7(1), 5594 (2017).
doi: 10.1038/s41598-017-06052-y
Liu, J. et al. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Peptides 106, 83–90 (2018).
doi: 10.1016/j.peptides.2018.07.001